drugset / Trial / NCT00458159
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes.
Timeline
- Start
- 2007-05-01
- Primary completion
- 2008-10-01
- Completion
- 2008-12-01
Outcome
Outcome not reported
Stopped: “The compound has a benign safety profile with short-term use, clinically sig efficacy responses have not been demonstrated, or if so, have not been sustained.”
Publications
- Background Brandenburg N, et al. Venous thromboembolism in patients with myelodysplastic syndrome treated with lenalidomide: Incidence and risk factors. Presented at 2008 ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL. Abstract No. 7084.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CC-11006 | Small molecule | 10 mg | Oral |
| Subject | CC-11006 | Small molecule | 15 mg | Oral |
| Subject | CC-11006 | Small molecule | 25 mg | Oral |
| Subject | CC-11006 | Small molecule | 35 mg | Oral |
| Subject | CC-11006 | Small molecule | 50 mg | Oral |